Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. - Wikidata - awgldk - TriplyDB

Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

http://www.wikidata.org/entity/Q45921089

about

Protective Effects of Streblus asper Leaf Extract on H2O2-Induced ROS in SK-N-SH Cells and MPTP-Induced Parkinson's Disease-Like Symptoms in C57BL/6 Mouse Behavioral phenotyping of mouse models of Parkinson's disease.A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Neuroprotective changes in degeneration-related gene expression in the substantia nigra following acupuncture in an MPTP mouse model of Parkinsonism: Microarray analysis Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models.MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain.Olfaction in Parkinson's disease and related disorders.Animal models of the non-motor features of Parkinson's disease.Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model Effects of L-arginine pre-treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's diseases in Balb/c mice Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology.Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease.Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration Non-motor features of Parkinson disease.Vascular-derived TGF-β increases in the stem cell niche and perturbs neurogenesis during aging and following irradiation in the adult mouse brain Beneficial effects of L-arginine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuronal degeneration in substantia nigra of Balb/c mice.MPTP modulates hippocampal synaptic transmission and activity-dependent synaptic plasticity via dopamine receptors.Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.Six weeks of voluntary exercise don't protect C57BL/6 mice against neurotoxicity of MPTP and MPP(+).Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.Exercise Improves Cognitive Impairment and Dopamine Metabolism in MPTP-Treated Mice.Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia.Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism.Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

P2860

Q30393313-511D4301-17A1-4849-B47B-47E2C180635B Q33820609-2A178463-DC5A-4314-9A11-D0501FE3A01E Q34094065-A9FBC73C-8675-484D-B883-2E478FC77361 Q34307633-6B3EF75C-D0A6-4220-8C51-6A6E15D48543 Q34476771-7D15DC93-9F01-4088-ADAF-9AE788D481C7 Q34654923-8F277EF3-13B7-4C4D-A169-F05F44D6D56B Q35035322-EE60C262-0AF4-4829-8F5F-8679C96B6282 Q35069025-2B4A3C8C-AF36-45F6-B02E-D1F7BB9C3B49 Q36193915-DE303ED0-85E2-434B-B3C1-9B9A4A5F9AC8 Q36235578-BAF10AA6-77B8-4927-9365-A85561C56B17 Q36342695-55D04917-9D3D-4630-ADD7-D09991F3C507 Q36582947-C706ACE2-9980-4FEA-A617-7F769C65AA69 Q37946305-700B03FE-BE3B-4749-A936-E1B01287047C Q38153587-4E0B6489-F85C-4A9C-9365-B83DC5FEE5E7 Q39273083-CA1E0077-AD26-41E0-9A12-C08C0DDC156B Q39327711-80A256D1-718B-4390-9EC2-C24D35BAE2EA Q39358549-89A483F8-509E-4382-AAA5-C7C6DDE81F13 Q39445832-5A0962BF-F4B0-46F1-BCB0-B55B7125905A Q41108404-4F48A71D-7CD8-4DA7-B0A2-FA63B8DCDD88 Q42507271-89A00AEA-4DD8-4987-A97B-362FA83ED39B Q42866001-3C9726DE-B08C-49E3-AA3B-2B79B4982B81 Q44688192-B7322698-D3C1-44D8-9743-2F4040F1AD27 Q46256354-32E8F8FD-0609-4044-90D0-F5B2A1E42F74 Q47606267-9DEBC5E9-1537-4FDB-A35F-8DA9851C6F2E Q48109313-98F23A8E-B60A-4030-B8C2-7CE0C7DAA0D4 Q48200129-3D90785A-39D0-40D9-9C1E-AB4EC33E1C36 Q50235339-41132BF9-C7A3-4497-9C91-796A03C0F5A8 Q50862423-51540B4C-903D-4395-9D20-11DF8740C9B7 Q51020610-05C0AECD-61BA-4BFA-9E64-C51223E68661 Q51066799-9F42A56A-405D-45D4-AF51-32B526440DCC Q52148873-E4B7D668-AB8C-4217-9CB9-8B6583312190

P2860

Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

http://www.wikidata.org/entity/Q45921089

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Single intranasal administrati ...... phase of Parkinson's disease.

@en

Single intranasal administrati ...... phase of Parkinson's disease.

@nl

type

label

Single intranasal administrati ...... phase of Parkinson's disease.

@en

Single intranasal administrati ...... phase of Parkinson's disease.

@nl

altLabel

Single Intranasal Administrati ...... l Phase of Parkinson’s Disease

@en

prefLabel

Single intranasal administrati ...... phase of Parkinson's disease.

@en

Single intranasal administrati ...... phase of Parkinson's disease.

@nl

P1433

Q45921089-E060300B-14B0-431F-B014-30800071C7AE

P1476

Q45921089-329A65ED-5C5D-4C03-9BDC-65261C10D627

P2093

Q45921089-2A63F827-63F0-416D-B6BB-452D85E89C9E

Q45921089-3058D372-1646-4450-9C15-7AC96264301D

Q45921089-3DAC5CFC-DF4F-4D64-BE51-1F16C4DB70A9

Q45921089-8EA3691E-8122-41E6-8A62-D7BF9EBF5F05

Q45921089-B63887DF-EF50-4484-B20A-3D4DB7B1C361

Q45921089-CB13C8BE-5CEE-42B9-A7E2-0000466236A1

Q45921089-D1D3BEF0-35AE-4AAC-BFE7-6ACC318FFB4F

Q45921089-DBECEF5E-49E4-4402-9CDB-EBCFF004D9B4

Q45921089-E2A6AE58-DB78-44DB-9C4C-0B8AEF94C2A9

Q45921089-FEABF806-8815-4303-871A-088CA3CF75BB

P2860

Q45921089-121D9765-B1B5-4CC8-AC5B-3CC645FAC2DC

Q45921089-1C23D772-03EE-4C4E-87AF-01C9FE9A589E

Q45921089-220B1927-BBFE-4D3A-8B67-95B1E095FEC9

Q45921089-29B0D95F-0D87-4486-99FF-B300ED810C96

Q45921089-75D5C207-6919-41F6-AE84-653287D61D56

P2888

Q45921089-F89D3C01-6D19-4330-A620-AAAB8A223F0C

P304

Q45921089-A6067B19-AB05-404E-BE4D-C290C7F2432D

P31

Q45921089-CE2A9CA0-B2BC-4E51-81CB-D09413B0B057

P356

Q45921089-57E3679F-3BC4-4814-B855-92F0D2260964

P433

Q45921089-4E338390-827F-4EFB-A8E4-B0B971C46D2F

P478

Q45921089-C2860673-8881-4A3B-BAB0-DCBBF9DD4D83

P50

Q45921089-3A9FC6B6-CD81-4329-825D-81844B01CCB1

Q45921089-815F8FEE-63C4-44CE-98A3-0FE77E2DA8A3

P577

Q45921089-A654D263-6FCA-44CD-BF69-43B51B94C4B2

P5875

Q45921089-6F1EEA8B-E766-45CE-AB99-2C99FB5991AC

P6179

Q45921089-8B420FC9-BDD9-4340-A5DD-0202B748D6C8

P698

Q45921089-458058AE-E360-41D0-8CAC-ACEEA49113E6

P921

Q45921089-AC799FB6-E091-432A-83F9-8C38B1202349

P356

S12640-009-9087-0

P1433

Neurotoxicity Research

P1476

Single intranasal administrati ...... l phase of Parkinson's disease

@en

P2093

Aderbal S Aguiar

http://www.w3.org/2001/XMLSchema#string

Argelia Esperanza Rojas-Mayorquin

http://www.w3.org/2001/XMLSchema#string

Caroline Chevarin

http://www.w3.org/2001/XMLSchema#string

Elaine Del Bel

http://www.w3.org/2001/XMLSchema#string

Filipe C Matheus

http://www.w3.org/2001/XMLSchema#string

Laure Ginestet

http://www.w3.org/2001/XMLSchema#string

Laurence Lanfumey

http://www.w3.org/2001/XMLSchema#string

Michel Hamon

http://www.w3.org/2001/XMLSchema#string

Raymond Mongeau

http://www.w3.org/2001/XMLSchema#string

Rita Raisman-Vozari

http://www.w3.org/2001/XMLSchema#string

P2860

Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration.

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living.

Psychiatric aspects of Parkinson's disease--an update.

Neurochemistry of the vertebrate olfactory bulb.

Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.

P2888

s12640-009-9087-0

P304

114-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12640-009-9087-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Rui Daniel Prediger

Claudia P Figueiredo

P577

2009-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26692821

http://www.w3.org/2001/XMLSchema#string

P6179

1017156609

http://www.w3.org/2001/XMLSchema#string

P698

19629612

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease